Kane Biotech Inc. (CVE:KNE – Get Free Report)’s stock price traded up 16.7% on Wednesday . The stock traded as high as C$0.04 and last traded at C$0.04. 1,263,508 shares changed hands during trading, an increase of 524% from the average session volume of 202,403 shares. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The stock’s 50-day moving average is C$0.03 and its 200 day moving average is C$0.04. The company has a debt-to-equity ratio of -308.66, a quick ratio of 0.39 and a current ratio of 0.68. The stock has a market capitalization of C$6.36 million, a PE ratio of -1.75 and a beta of 1.03.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
